Trial
NCT02521233
Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
EMS
Collaborators
—
Condition
Essential Arterial Hypertension
Intervention
Candesartan + Chlorthalidone (8mg+12,5mg)
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-01-19